Retention adherence to therapy as a guarantee of the SLIT efficacy
- Authors: Pavlova KS1, Mdinaradze DS1
-
Affiliations:
- NRC Institute of Immunology FMBA of Russia
- Issue: Vol 16, No 2 (2019)
- Pages: 61-66
- Section: Articles
- URL: https://journal-vniispk.ru/raj/article/view/121504
- DOI: https://doi.org/10.36691/RJA1199
- ID: 121504
Cite item
Full Text
Abstract
According to WHO at last 50% of the patient don't follow doctor’s recommendations. Ultimately, this leads to a decrease or absence of the treatment effect. In this regard, all the latest international and national guidelines mention the need to take into account the patient’s preferences in the choice of therapy. Allergen-specific immunotherapy (AIT) is one of the main methods of treatment of allergic diseases such as allergic rhinitis, allergic conjunctivitis and atopic asthma, and has disease modifying properties and the long-term efficacy after stop treatment. AIT refers to a preventive and long-term method (recommended for at least 3 years), that is often the cause of reduced adherence to therapy. Various studies have confirmed the dose-dependent effect of AIT, and, consequently, changes in regimens or shortening of therapy may affect the end result. In case of insufficient effectiveness of AIT, the probability of low compliance should be considered first of all. Sublingual AIT (SLIT) requires the patient to be highly involved in the treatment process. The task of the doctor in this case is increasing therapeutic cooperation, as one of the most important factors to ensure the effectiveness of SLIT. The main methods in this case are to improve the patient’s understanding of the purpose of the therapy and regular monitoring by the doctor.
Full Text
##article.viewOnOriginalSite##About the authors
K S Pavlova
NRC Institute of Immunology FMBA of Russia
Email: ksenimedical@gmail.com
кандидат медицинских наук, старший научный сотрудник отделения бронхиальной астмы.
D S Mdinaradze
NRC Institute of Immunology FMBA of Russiaординатор отделения бронхиальной астмы.
References
- Аллергия и аллерген-специфическая иммунотерапия. Под ред. Гущина И.С., Курбачёвой О.М. М.: Издательство «Фармарус Принт Медиа». 2010:228
- Eifan AO, Calderon MA, Durham SR. Allergen immunotherapy for house dust mite: clinical efficacy and immunological mechanisms in allergic rhinitis and asthma. Expert Opin Biol Ther. 2013;13(11):1543-1556. doi: 10.1517/14712598.2013.844226.
- Jutel M., Agache I., Bonini S., Burks AW, Calderon M., Canonica W. International Consensus On (ICON) Allergy Immunotherapy (AIT). J. Allergy Clin Immunol. 2015;136(3):556-568. doi: 10.1016/j.jaci.2015.04.047.
- Jutel M., Agache I., Bonini S., Burks AW, Calderon M., Canonica W. International Consensus On (ICON) Allergy Immunotherapy (AIT) II: mechanisms, standardization and pharmacoeconomics. J. Allergy Clin Immunol. 2016;137:358-368. doi: 10.1016/j.jaci.2015.12.1300.
- Novembre E., Galli E., Landi F., Caffarelli C., Pifferi M., De Marco E. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinocon-junctivitis. J. Allergy Clin Immunol. 2004;114:851-857. doi: 10.1016/j.jaci.2004.07.012.
- Wahn U, Bachert C, Heinrich J, Richter H, Zielen S. Real-world benefits of allergen immunotherapy for birch pollen associated allergic rhinitis and asthma. Allergy. 2018;00:1-11. doi: 10.1111/all.13598.
- Kiel MA, Roder E., van Gerth WR et al. Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy. J. Allergy Clin Immunol. 2013;132(2):353-360.
- Zielen S., Devillier P., Heinrich J., Richter H., Wahn U. Sublingual immunotherapy provides long-term relief in allergic rhinitis and reduces the risk of asthma: a retrospective, real-world database analysis. Allergy. 2018;73(1):165-177. DOI: 10.1111 / all.13213.
- Adherence to long-term therapies: Evidence for action. Geneva: World Health Organization. 2003:212.
- Sackett DL, Haynes RB. Introduction and the magnitude of compliance and noncompliance. In: Compliance with therapeutic regimens. Baltimore: Johns Hopkins University Press. 1976:1-25.
- Данилов ДС. Терапевтическое сотрудничество (комплаенс): содержание понятия, механизмы формирования и методы оптимизации. Неврология, нейропсихиатрия, психосоматика. 2014;2:4-12
- Ястребов ВС. Проблемы патернализма и партнерства в психиатрии. Психиатрия. 2012;4(56):7-13
- Vita D., Caminiti L., Ruggeri P. et al. Sublingual immunotherapy: adherence based on timing and monitoring control visits. Allergy. 2010;65(5):668-669.
- Incorvaia C., Rapetti A., Scurati S., Puccinelli P., Capecce M., Frati F. Importance of patient’s education in favouring compliance with sublingual immunotherapy. Allergy. 2010:65:13411342. doi: 10.1111/j.1398-9995.2010.02347.x.
- Savi E., Peveri S., Senna G., Passalacqua G. Causes of SLIT discontinuation and strategies to improve the adherence: a pragmatic approach. Allergy. 2013;68:1193-1195.
Supplementary files
